A 76-year-old patient with metastatic lung cancer was treated with pembrolizumab. After the second cycle was found to have elevated glucose levels without evidence of polyuria and polydipsia, the patient was diagnosed with ICI‐induced type 1 diabetes that was corrected with insulin and the patient continued with their next cycle of pembrolizumab. The gene discussed is INS; the disease is Polydipsia.